Elewski B, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, and Strober B. (2017) Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab. Journal of Dermatological Treatment. http://dx.doi.org/10.1080/09546634.2017.1294727
When the above article was first published online, B. E. Strober was incorrectly affiliated to Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. This has now been removed and corrected in the online version.
The authors apologise for this error.